From: The association between liver enzymes and risk of type 2 diabetes: the Namwon study
 | Q1 | Q2 | Q3 | Q4 | P for trend |
---|---|---|---|---|---|
AST (units/l) | ≤18 | 19 to 21 | 22 to 25 | ≥26 |  |
Cases/persons at risk | 74/983 | 58/1,066 | 86/1,187 | 95/1,104 | Â |
Model 1 | 1 | 0.69 (0.48-0.98) | 0.92 (0.67-1.28) | 1.11 (0.80-1.52) | 0.212 |
Model 2 | 1 | 0.66 (0.46-0.95) | 0.87 (0.62-1.22) | 0.99 (0.71-1.38) | 0.567 |
Model 3 | 1 | 0.72 (0.49-1.05) | 0.88 (0.62-1.25) | 1.01 (0.72-1.43) | 0.562 |
Model 4 | 1 | 0.67 (0.45-0.99) | 0.83 (0.57-1.12) | 0.95 (0.66-1.37) | 0.783 |
ALT (units/l) | ≤13 | 14 to 16 | 17 to 21 | ≥22 |  |
Cases/persons at risk | 56/1,199 | 52/994 | 77/1,003 | 128/1,127 | Â |
Model 1 | 1 | 1.12 (0.76-1.65) | 1.69 (1.18-2.40) | 2.65 (1.91-3.67) | <0.001 |
Model 2 | 1 | 0.99 (0.67-1.47) | 1.40 (0.97-2.01) | 1.86 (1.32-2.61) | <0.001 |
Model 3 | 1 | 0.97 (0.64-1.48) | 1.38 (0.94-2.02) | 1.86 (1.31-2.65) | <0.001 |
Model 4 | 1 | 0.86 (0.56-1.32) | 1.23 (0.83-1.83) | 1.49 (1.03-2.16) | 0.006 |
GGT (units/l) | ≤12 | 13 to 15 | 16 to 21 | ≥22 |  |
Cases/persons at risk | 45/1,248 | 42/882 | 85/1,076 | 141/1,117 | Â |
Model 1 | 1 | 1.35 (0.88-2.07) | 2.30 (1.59-3.33) | 3.88 (2.74-5.49) | <0.001 |
Model 2 | 1 | 1.14 (0.74-1.77) | 1.73 (1.18-2.54) | 2.69 (1.86-3.89) | <0.001 |
Model 3 | 1 | 1.11 (0.70-1.76) | 1.60 (1.06-2.39) | 2.45 (1.66-3.61) | <0.001 |
Model 4 | 1 | 0.97 (0.60-1.55) | 1.27 (0.83-1.94) | 1.85 (1.23-2.79) | <0.001 |